In a narrow but clearly defined group of patients, yes. Very early, low-grade uterine cancer in young women who want to preserve fertility can be managed with hormonal therapy rather than surgery. The criteria are strict. Outside them, hysterectomy remains the standard treatment.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Uterine preservation in endometrial cancer is not a compromise. For the right patient, grade 1 stage IA disease with no myometrial invasion, hormonal therapy has published response rates above 70 percent and pregnancy outcomes that are genuinely encouraging. But patient selection is everything. This is not a route for any uterine cancer patient who wants to avoid surgery. The tumour board has to confirm the case fits the criteria before we consider it.”

Strict criteria apply. All four need to be met.

• Grade 1 endometrioid adenocarcinoma only: The most common and least aggressive subtype. High-grade histology, serous, clear cell or carcinosarcoma, are not candidates. Those need surgery without exception.
• Stage IA, no myometrial invasion: Cancer confined to the endometrium, not grown into the uterine muscle wall. MRI confirms this. Any myometrial invasion, even superficial, puts the patient outside preservation criteria.
• Strong desire to preserve fertility: Uterine preservation is a fertility-sparing decision, not a convenience one. Patients who have completed their family are offered hysterectomy, which remains the most reliable cure with the lowest recurrence risk.
• Willingness for intensive surveillance: Hormonal therapy requires hysteroscopy and biopsy every 3 to 6 months to confirm response. No response within 6 months means surgery. Patients must commit to this schedule fully.

For patients who proceed to minimally invasive robotic hysterectomy after hormonal therapy fails or at any stage of uterine cancer, robotic cancer surgery delivers precise pelvic surgery with faster recovery than open approaches.

Most uterine cancer patients fall here. The indications are clear.

• Stage IB and above: Cancer has grown into the myometrium or beyond. Hormonal therapy cannot reach or control disease that has invaded the muscle wall or spread further. Surgery is the only curative option.
• High-grade histology: Grade 2, grade 3, serous, clear cell or carcinosarcoma subtypes. Aggressive biology. Hormonal therapy has no meaningful role. Robotic radical hysterectomy with lymph node dissection is the standard approach.
• Failed hormonal therapy: No complete response confirmed on biopsy by 6 months. Continuing hormonal therapy beyond this risks allowing disease to progress. Hysterectomy is offered without further delay.
• Completed family or no fertility wish: For women who don’t need fertility preservation, hysterectomy removes the cancer and eliminates the risk of recurrence in the remaining uterus. The safest path when fertility isn’t the goal.

For patients who want to understand what uterine cancer curability means across stages and treatment types, our blog on uterine cancer curable explains the full picture.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic radical hysterectomy with lymph node dissection for uterine cancer, evaluates every eligible young patient for hormonal preservation at the tumour board, and ensures fertility goals are part of the treatment conversation from the very first consultation.

That fertility-first discussion at diagnosis, not as an afterthought once the surgical plan is already set, is what gives young women with uterine cancer a real choice rather than a decision made for them. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Bladder preservation is possible in bladder cancer, and for the majority of patients it’s the standard path. Around 75 percent of diagnoses are non-muscle invasive. The tumour hasn’t reached the bladder muscle. Those cases are almost always managed without removing the bladder. Even muscle invasive disease has a preservation route, chemoradiation combined with initial surgery, that delivers comparable outcomes to cystectomy in the right patients.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Bladder removal is not the automatic answer for every muscle invasive bladder cancer. Trimodal therapy, TURBT followed by concurrent chemoradiation, has published outcomes comparable to cystectomy in the right patient. The decision rests on tumour characteristics, bladder function, patient fitness, and whether the cancer responds to the initial resection. The tumour board makes that call with all four factors on the table.”

Three situations support bladder preservation. Each has clear criteria.

• Non-muscle invasive bladder cancer: Stages Ta, T1 and carcinoma in situ. The tumour hasn’t grown into the bladder muscle. TURBT removes it endoscopically. No open surgery, no cystectomy. Intravesical BCG or chemotherapy follows to reduce the chance of it coming back.
• Trimodal therapy for muscle invasive: TURBT removes as much visible tumour as possible. Concurrent chemoradiation follows. Works best in single tumours, no hydronephrosis, complete or near-complete initial resection and a bladder that still functions well.
• Partial cystectomy in rare cases: A small number of patients with a single accessible tumour and adequate remaining bladder capacity can have just that segment removed. Strict patient selection. Not the majority.
• Response-guided approach: Some centres restage with cystoscopy and biopsy after initial treatment. Complete responders are followed closely. Salvage cystectomy is available if disease persists or returns.

For patients whose bladder cancer requires robotic surgery whether TURBT, partial or radical cystectomy, robotic cancer surgery brings precision and faster recovery compared to open approaches.

Some situations make bladder removal the safest clinical choice.

• Muscle invasive, not trimodal-eligible: Multifocal tumours, hydronephrosis, incomplete initial TURBT, or poor bladder function. These features make chemoradiation unlikely to achieve durable control. Radical cystectomy is the standard.
• No response to chemoradiation: If restaging after trimodal therapy shows residual or recurrent muscle invasive disease, salvage cystectomy becomes necessary. Continuing bladder preservation after a failed response adds risk without benefit.
• High-grade recurrent non-muscle invasive: Multiple BCG failures with high-grade recurrent disease or progression toward muscle invasion. The bladder is no longer responding to bladder-sparing treatment. Cystectomy earlier is better than cystectomy later.
• Extensive or locally advanced disease: T4 tumours involving adjacent organs, or disease where the bladder itself is structurally compromised. Preservation is no longer functionally or oncologically sound.

For patients at the earliest stage where preservation is most achievable, our blog on bladder cancer warning signs explains what early symptoms look like and why they matter so much.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic TURBT, robotic partial cystectomy and robotic radical cystectomy for bladder cancer, evaluates every muscle invasive case for trimodal therapy eligibility at the tumour board, and ensures bladder preservation is considered before cystectomy is recommended.

That preservation-first conversation at the first consultation, rather than defaulting to cystectomy as the path of least resistance, is what gives bladder cancer patients a complete picture of their options before any decision is made. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Robotic lung cancer surgery is available in India. Not everywhere, but at select surgical oncology centres that have invested in the platform and the surgical volume to use it properly. The procedure is called RATS, Robotic-Assisted Thoracoscopic Surgery. Small port incisions in the chest wall. No rib spreading. No large open cut. Stage I and II non-small cell lung cancer is where it works best, provided lung function holds up and the tumour sits in an accessible location.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Robotic and VATS approaches have replaced open thoracotomy as the standard for operable early-stage lung cancer at high-volume centres. The chest is a space where robotic instruments genuinely outperform human hands in terms of reach and precision. Patients who qualify for robotic lung surgery avoid the rib spreading of open surgery. That’s the main driver of pain and the prolonged recovery that used to come with chest operations.”

Not every lung cancer patient fits. Several factors decide it.

• Stage I or II non-small cell lung cancer: Early stage disease, confined to the lung or with limited lymph node involvement. Robotic surgery is used with curative intent here. Stage III or IV with widespread spread needs systemic treatment first, surgery comes later if at all.
• Adequate lung function: Pulmonary function tests, FEV1 and DLCO specifically, confirm the patient can tolerate losing a lobe. The remaining lung has to handle the full load afterwards.
• Accessible tumour location: Peripheral tumours in the outer lung zones are the cleanest robotic candidates. Central tumours near major vessels or the main airway may need open surgery for safety.
• No prior major chest surgery: Previous thoracotomy, thick pleural adhesions or significant scarring make port placement risky. Working space collapses. These cases often go open from the start or convert mid-procedure.

For patients whose lung cancer workup leads to a surgical decision, robotic cancer surgery covers all thoracic cancer types including lung, oesophageal and mediastinal tumours.

The operation and recovery look very different from open chest surgery.

• The procedure: Three to four small port incisions. Robotic arms go in. No rib spreading at any point. The affected lobe, segment or wedge is removed with complete lymph node dissection. Two to four hours in theatre depending on how much lung comes out.
• Discharge timeline: Most robotic lobectomy patients go home in 3 to 5 days. Open thoracotomy? Seven to ten. The gap is directly explained by the absence of rib spreading and the smaller wounds.
• Pain and function: Significantly less post-operative pain. Oral analgesia within 24 to 48 hours for most patients. Shoulder and arm movement returns faster because the chest wall muscles aren’t divided the way open surgery requires.
• Oncological outcomes: Lymph node clearance, resection margins, long-term survival. All equivalent to open surgery for the same stages. The advantage is in recovery. Not in cancer control. That’s the honest comparison.

For patients weighing robotic against open surgery for lung cancer or other cancers, our blog on open vs robotic surgery walks through the evidence side by side.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs VATS and RATS lobectomy, segmentectomy and wedge resection for lung cancer with full mediastinal lymph node dissection integrated into each operation, and has built robotic thoracic surgery into routine practice rather than treating it as an occasional procedure.

Surgical volume in robotic thoracic surgery matters more than in most specialties. The learning curve is steep and the chest leaves little room for error. Patients who choose a surgeon doing this at real volume get a different operation from one done occasionally. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Total thyroidectomy removes the entire thyroid gland. Partial, also called hemithyroidectomy or thyroid lobectomy, removes one lobe and leaves the other. For most thyroid cancers, total thyroidectomy is the standard. Partial is acceptable for small, low-risk papillary cancers under 1 cm confined to one lobe with no lymph node involvement. The decision comes down to tumour size, type, stage, and whether radioiodine is needed afterwards.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Total thyroidectomy is the standard for most thyroid cancers because it allows radioiodine to be used afterwards and removes any bilateral disease that imaging might have missed. Partial thyroidectomy works for carefully selected low-risk cases, but the criteria are strict. A patient who looks like a partial case on ultrasound sometimes turns out to need total once the pathology comes back, and then a second operation becomes the only option.”

Most thyroid cancer patients fall into this category.

• Tumours over 1 cm: The ATA guidelines recommend total thyroidectomy for papillary thyroid cancer over 1 cm. Larger tumours have higher recurrence risk and benefit from complete gland removal and radioiodine.
• Bilateral or multifocal disease: Papillary thyroid cancer is commonly multifocal. Leaving one lobe in place when disease may be present bilaterally increases recurrence risk sharply.
• Aggressive histology: Follicular cancer, Hurthle cell cancer, medullary thyroid cancer, poorly differentiated or anaplastic thyroid cancer. All of these need total thyroidectomy without exception.
• Radioiodine needed post-operatively: When radioiodine ablation or treatment is part of the plan, the entire gland must be gone first. Partial thyroidectomy makes radioiodine ineffective because the normal remaining lobe absorbs it all.

For patients choosing scarless thyroid surgery, robotic cancer surgery includes the RABIT technique, a robotic-assisted scarless thyroidectomy performed through the axilla with no incision on the neck.

• Medication trade-off: Total thyroidectomy means lifelong levothyroxine. One tablet a day. For most patients it’s well tolerated. Partial avoids this but only if the remaining lobe functions normally, which isn’t guaranteed.
• Recurrence monitoring: After total thyroidectomy, thyroglobulin becomes a precise tumour marker. Any detectable thyroglobulin means cancer is back. This clean marker doesn’t exist after partial.
• Second surgery reality: If a partial case turns out to need total, the second operation in a previously operated neck carries significantly higher complication risk. Recurrent laryngeal nerve and parathyroid injury rates rise sharply on re-operation.
• Partial for the right patient: Papillary microcarcinoma under 1 cm, single lobe, no lymph node involvement, low-risk histology, patient fully informed. This narrow group genuinely does well with lobectomy alone.

For a full picture of how thyroid cancer surgery achieves cure and what happens to surveillance afterwards, our blog on thyroid cancer surgery walks through the complete picture.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs total thyroidectomy, completion thyroidectomy, thyroid lobectomy and RABIT at high volume, invented the RABIT scarless robotic thyroidectomy technique himself, and integrates neck dissection into the primary surgical plan for every case where staging and pathology indicate it.

That surgical volume matters in thyroid cancer more than most cancers. The decision between total and partial thyroidectomy looks simple on paper. In the operating room, it depends on what the surgeon actually finds, and a surgeon who has done thousands of thyroid operations reads those intraoperative signals differently from one who does them occasionally. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Early stage cervical cancer can often be treated without removing the uterus. For very early disease, conisation or cone biopsy removes the cancerous tissue while the uterus stays completely intact. For slightly larger early tumours in women who want to preserve fertility, trachelectomy removes only the cervix while leaving the uterus in place. For locally advanced disease that doesn’t need surgery, chemoradiation is the standard treatment and the uterus isn’t removed at all. Hysterectomy becomes the standard option from stage IB2 upward or when the tumour exceeds certain size thresholds.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “The first question many young women ask after a cervical cancer diagnosis is whether they’ll lose their uterus. For a significant number of them, the honest answer is no. Stage, tumour size, lymph node status and fertility wishes all go into that discussion. It’s not a yes or no question at diagnosis. It’s a conversation the tumour board has with each patient’s specific pathology in front of them.”

Stage and tumour size determine which options are on the table.

• Conisation for stage IA1: Very early superficial cancer confined to the cervix. A cone-shaped piece of cervical tissue is removed. Uterus stays. Pregnancy remains possible. Cure rates above 95 percent for this stage.
• Trachelectomy for stage IA2 to IB1: Removes the cervix, upper vagina and surrounding tissue while the uterus stays in place. For tumours under 2 cm in carefully selected patients. Fertility preserved. Second trimester pregnancy risk needs cervical cerclage.
• Chemoradiation for locally advanced disease: From stage IB3 onward, concurrent cisplatin-based chemotherapy with radiation replaces surgery as the primary treatment. The uterus isn’t removed. Ovarian function may be affected but the uterus remains.
• Simple hysterectomy for low-risk early disease: A 2024 NEJM trial confirmed simple hysterectomy equals radical hysterectomy in recurrence outcomes for low-risk stage IB1 tumours under 2 cm. Less tissue removed, fewer side effects, same cure rate.

For patients undergoing robotic-assisted radical trachelectomy or radical hysterectomy where minimally invasive surgery is indicated, robotic cancer surgery brings nerve-sparing precision and significantly faster recovery than open surgery.

Some situations make hysterectomy the safest and most appropriate path.

• Tumours over 2 cm at stage IB2: Larger tumours have a higher risk of parametrial spread and lymph node involvement. Radical hysterectomy with pelvic lymph node dissection is the standard surgical approach here.
• Completed family, no fertility concern: For women who have completed childbearing, radical hysterectomy offers definitive treatment and removes the risk of future cervical cancer in the remaining uterus.
• Radiation-resistant or recurrent disease: When cervical cancer recurs after primary chemoradiation, pelvic exenteration or radical hysterectomy may be the only curative surgical option left.
• Advanced local disease requiring surgery: Stage IVA disease involving the bladder or rectum may need exenteration surgery. The uterus is removed as part of a wider resection.

For more on how HPV vaccination prevents the cervical cancer that makes these decisions necessary in the first place, our blog on HPV vaccine cervical cancer covers the prevention picture in full.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic-assisted radical hysterectomy, radical trachelectomy, and fertility-sparing cervical surgery using minimally invasive techniques, and presents every cervical cancer case to the tumour board so the fertility conversation happens before any treatment decision is finalised.

That fertility-first discussion at the first consultation, not as an afterthought after the surgical plan is already set, is what gives young women with cervical cancer a realistic picture of what their options actually are. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.